What is HC Wainwright’s Estimate for PSTV FY2030 Earnings?

Plus Therapeutics, Inc. (NASDAQ:PSTV) – Research analysts at HC Wainwright issued their FY2030 EPS estimates for Plus Therapeutics in a research note issued on Monday, March 16th. HC Wainwright analyst S. Lee anticipates that the company will post earnings per share of $0.22 for the year. HC Wainwright currently has a “Buy” rating and a $1.00 price objective on the stock. The consensus estimate for Plus Therapeutics’ current full-year earnings is ($2.30) per share.

Other analysts have also recently issued reports about the company. Ascendiant Capital Markets lowered their target price on Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating on the stock in a research report on Friday, November 21st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Thursday, January 22nd. Lake Street Capital assumed coverage on Plus Therapeutics in a report on Tuesday, February 3rd. They set a “buy” rating and a $2.00 price target on the stock. Finally, D. Boral Capital cut their price objective on shares of Plus Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, January 22nd. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Plus Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.80.

Plus Therapeutics Trading Down 4.1%

Shares of NASDAQ PSTV opened at $0.25 on Tuesday. Plus Therapeutics has a 12-month low of $0.16 and a 12-month high of $2.08. The company has a market cap of $42.89 million, a PE ratio of -0.20 and a beta of 0.78. The stock has a 50 day simple moving average of $0.30 and a 200-day simple moving average of $0.48.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. L1 Global Manager Pty Ltd acquired a new stake in Plus Therapeutics in the 4th quarter valued at approximately $1,167,000. Jane Street Group LLC bought a new position in shares of Plus Therapeutics during the 4th quarter worth approximately $525,000. Altium Capital Management LLC acquired a new stake in shares of Plus Therapeutics in the third quarter valued at approximately $628,000. Geode Capital Management LLC lifted its position in shares of Plus Therapeutics by 72.5% in the fourth quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock worth $719,000 after purchasing an additional 589,544 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in Plus Therapeutics during the fourth quarter worth $254,000. 3.28% of the stock is currently owned by institutional investors.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.